Group items tagged

Men with Metabolic Syndrome have lower Total Testosterone values.  Symptoms correlated with age: older men associated with increased symptoms.  This study only found lot T at 6.5%.  The authors in this study have come up with a new box--andropenia.  I don't know what the heck that is and how that helps clients.  If symptoms are present and if levels are on the decline, then symptomatic hypogonadism is present.  I know the logic seems simple, but it appears hard to follow in the science.  I don't see this any different then type II diabetes.  At 126 you have diabetes, but at 125, we don't know what to do with you but see us next year and you will have diabetes and we will know what to do because you are in the box of diabetes.

low T appears to be associated with cognitive decline in men.  If low T is present on testing, then therapy is appropriate to improve cognition.

Lead levels lead to increased risk of cardiovascular events at lower than previous thought levels.  Levels as low as 2mcg/dl found to be associated with increased cardiovascular mortality.  This equates to 38% of Americans.  The author concludes with this statement, "Although a 10-fold decline in blood lead levels has occurred in the United States in recent decades, current levels remain orders of magnitude higher than in pre industrialized times".

Some startling statistics in this 2013 review on Testosterone in men.  Studies reflect an inverse relationship between Testosterone and CAD severity.  That is, the lower the Testosterone levels, the increase in severity of CAD. This same association was also found with CHF.  Low Testosterone is common in those with CAD, CHF, type II diabetes, increased IMT in carotids and aorta, and obesity when compared to "healthy" individuals.  Testosterone therapy in those with CAD found benefits: prolongation of ST segment depression, coronary vasodilation, improved exercise capacity in those with CHF, shift to type I muscle fibers, shorten the QTc interval.  Testosterone therapy has been shown to improve insulin resistance, improve HgbA1c and decrease waist circumference and fat loss in obese individuals.  Otherwise, a good review of the association between a declining Testosterone and cardiovascular disease.

Chemotherapy is associated with a decline in lean body mass.  This could play a role in increase weight, especially in pre menopause women.

Increasing BPA levels associated with declining androstenedione levels,but positively associated with SHBG levels in exposed men.

hepatitis associated with a decline in total Testosterone.  This was a positive correlation with worsening hepatitis.  Free Testosterone was not effected.  Interesting, SHBG increased.

The costs of health care continue to increase, while the health of Americans continues to decline.  Yet, we continue to follow the same path.

declining serum Estradiol associated with increased cardiovascular fat in postmenopausal women.

Interesting study looked at Total Testosterone (TT) and free Testosterone (FT) in older men in BMD assessment.  The authors found no change in TT, but a significant decline in free Testosterone.  This fits with other research pointing to free Testosterone as a better functional assessment tool.

In men <45, a declining Testosterone level is associated with an increasing incidence of Metabolic syndrome.  This association was independent of age.  Testosterone was positively associated with HDL and inversely associated with BMI, waist circumference, Triglycerides, Trigylceride:HDL cholesterols, and glucose.

Radiation for prostate cancer associated with decline in serum Total Testosterone at 6 months, which resolved at 12 months.

Low free and Total Testosterone levels found to be associated with premature CAD in men.  Some confounders were present, which they tried to account for--this should leave some healthy questioning of this study results.  That being said, this is not the first time low T has been found to be associated with CAD in men.  This study found a statistical significant association with Free and Total Testosterone levels in young men.  Another point to consider is the Low T a cause or a biomarker and an effect of poor/declining health?  I would so more to the biomarker point.

Maybe the risks of estrogen metabolism is age dependent?  This Long Island Breast Cancer Study Project found that an increased 2:16alphOH-estrone ratio was associated with a reduced premenopausal, invasive breast cancer risk.  This association declined when looked at in postmenopausal women.

Study finds that low free T and low Total T were associated with decline in desire, ED and activity versus none with Estradiol and SHBG in older men.  The difficult issue is the threshold of "low T".  The definition of "low T" is not uniform and varies with age.  Thus baseline evaluations and correlation with symptoms, metabolic dysfunction must be done.

meta-analysis finds decline in sperm count.

Study finds that declining Testosterone levels and increasing TNF-alpha and CRP are associated with shorter end-stage cancer survival.  Testosterone is not the same in men and women.  The effects on inflammatory cytokines are different.  This study should be divided into women and men to better differentiate these effects.

Melanoma is a known estrogen sensitive cancer.  This study finds ER Beta loss correlates with thickness of lesion.  The authors propose ERalpha/ERbeta ratio be assessed.  ERbeta has been shown to decrease proliferation, promotes differentiation, and decrease inflammation in breast studies.  In contrast, ERalpha promotes proliferation, decreases differentiation, and promotes inflammation.  Here, the same effects seem to apply to melanoma. Of interesting note, men have lower skin ERbeta than women and ERbeta declines with age and menopause in women.  Essentially, the loss of the ability to differentiate, decrease proliferation and inflammation  occurs with increase estrogen stimulus--set up for estrogen promoting cancers.

Nice review of Testosterone levels and some of the evidence linking Diabetes with low T.  However, the conclusion by the authors regarding what is causing the low T in men with Diabetes is baffling.  The literature does not point to one cause, it is clearly multifactorial--obesity, inflammation, high aromatase activity...I would suggest the authors continue their readings in the manner.